Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

被引：7
|
作者：
Woodford, Rachel [1 ]
Loh, Yanni [1 ]
Lee, Joanna [1 ]
Cooper, Wendy [2 ,3 ,4 ]
Marschner, Ian [5 ,6 ]
Lewis, Craig R. [7 ]
Millward, Michael [8 ,9 ]
Lord, Sally [5 ,10 ]
Gralla, Richard J. [11 ]
Yang, James C-H [12 ,13 ]
Mok, Tony [14 ]
Lee, Chee K. [1 ,5 ]
机构：
[1] St George Hosp, Canc Care Ctr, Sydney, NSW 2217, Australia
[2] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW 2050, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[4] Western Sydney Univ, Sch Med, Sydney, NSW 2751, Australia
[5] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 1450, Australia
[6] Macquarie Univ, Dept Stat, Sydney, NSW 2109, Australia
[7] Univ NSW, Prince Wales Hosp, Clin Sch, Sydney, NSW 2031, Australia
[8] Univ Western Australia, Sch Med, Perth, WA 6009, Australia
[9] Sir Charles Gairdner Hosp, Dept Med Oncol, Perth, WA 6010, Australia
[10] Univ Notre Dame, Sch Med, Sydney, NSW 2010, Australia
[11] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10461 USA
[12] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10002, Taiwan
[13] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10002, Taiwan
[14] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 20期
关键词：
chemoimmunotherapy; meta-analysis; non-small-cell lung cancer; PD-L1; expression; progression-free survival; AMERICAN SOCIETY; SQUAMOUS-CELL; OPEN-LABEL; NIVOLUMAB; CHEMOTHERAPY; DOCETAXEL; IMMUNOHISTOCHEMISTRY; PEMBROLIZUMAB; MECHANISMS; PHASE-1;
D O I：
10.2217/fon-2019-0105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n =4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.
引用
收藏
页码：2371 / 2383
页数：13
相关论文
共 50 条
  • [1] Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
    Califano, Raffaele
    Lal, Rohit
    Lewanski, Conrad
    Nicolson, Marianne C.
    Ottensmeier, Christian H.
    Popat, Sanjay
    Hodgson, Matthew
    Postmus, Pieter E.
    FUTURE ONCOLOGY, 2018, 14 (23) : 2415 - 2431
  • [2] PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
    Li, Jing
    Gu, Jian
    FUTURE ONCOLOGY, 2019, 15 (14) : 1667 - 1678
  • [3] Targeting PD-L1 for non-small-cell lung cancer
    Feld, Emily
    Horn, Leora
    IMMUNOTHERAPY, 2016, 8 (06) : 747 - 758
  • [4] Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer
    Scheel, Andreas H.
    Baenfer, Gudrun
    Baretton, Gustavo
    Dietel, Manfred
    Diezko, Rolf
    Henkel, Thomas
    Heukamp, Lukas C.
    Jasani, Bharat
    Joehrens, Korinna
    Kirchner, Thomas
    Lasitschka, Felix
    Petersen, Iver
    Reu, Simone
    Schildhaus, Hans-Ulrich
    Schirmacher, Peter
    Schwamborn, Kristina
    Sommer, Ulrich
    Stoss, Oliver
    Tiemann, Markus
    Warth, Arne
    Weichert, Wilko
    Wolf, Juergen
    Buettner, Reinhard
    Rueschoff, Josef
    HISTOPATHOLOGY, 2018, 72 (03) : 449 - 459
  • [5] Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
    Adam, J.
    Le Stang, N.
    Rouquette, I.
    Cazes, A.
    Badoual, C.
    Pinot-Roussel, H.
    Tixier, L.
    Danel, C.
    Damiola, F.
    Damotte, D.
    Penault-Llorca, F.
    Lantuejoul, S.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 953 - 958
  • [6] Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice
    Villaruz, Liza C.
    Hunter, Katerina Ancevski
    Kurland, Brenda F.
    Abberbock, Shira
    Herbst, Cameron
    Dacic, Sanja
    HISTOPATHOLOGY, 2019, 74 (02) : 269 - 275
  • [7] PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
    Aguiar, Pedro N., Jr.
    De Mello, Ramon Andrade
    Hall, Peter
    Tadokoro, Hakaru
    de Lima, Gilberto
    IMMUNOTHERAPY, 2017, 9 (06) : 499 - 506
  • [8] Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review
    Koomen, Bregje M.
    Badrising, Sushil K.
    van den Heuvel, Michel M.
    Willems, Stefan M.
    HISTOPATHOLOGY, 2020, 76 (06) : 793 - 802
  • [9] PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade
    Yoshida, Hironori
    Nomizo, Takashi
    Ozasa, Hiroaki
    Tsuji, Takahiro
    Funazo, Tomoko
    Yasuda, Yuto
    Ajimizu, Hitomi
    Yamazoe, Masatoshi
    Kuninaga, Kiyomitsu
    Ogimoto, Tatsuya
    Hosoya, Kazutaka
    Itotani, Ryo
    Sakamori, Yuichi
    Kim, Young Hak
    Hirai, Toyohiro
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 317 - 325
  • [10] The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer
    Lisberg, Aaron
    Garon, Edward B.
    JAMA ONCOLOGY, 2016, 2 (05) : 571 - 572
12345